Document is current
Any future updates will be listed below
-
Authors
Tang, Sunny X. https://orcid.org/0000-0002-4001-8120
Oliver, Lindsay D. https://orcid.org/0000-0003-2163-7257
Hänsel, Katrin
DeRosse, Pamela
John, Majnu
Khairullah, Ammar
Gold, James M. https://orcid.org/0000-0002-0109-9554
Buchanan, Robert W.
Voineskos, Aristotle https://orcid.org/0000-0003-0156-0395
Malhotra, Anil K.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH102313, R01MH102313, R01MH102313, R01MH102313, R01MH102313, R01MH102313)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
- License Information
-
More Information
Article History
Received: 28 September 2021
Revised: 23 May 2022
Accepted: 26 May 2022
First Online: 6 June 2022
Competing interests
: SXT is a consultant for Neurocrine Biosciences and North Shore Therapeutics, received funding from Winterlight Labs, and holds equity in North Shore Therapeutics. RWB is a DSMB member for Merck, Newron, and Roche; on the advisory board for Acadia, Avanir, Boehringer Ingelheim GBMH, GW Pharma, Minerva, and Roche; and consultant for Boehringer Ingelheim GMBH. AKM is a consultant for Acadia Pharmaceuticals, Genomind Inc, Informed DNA, and Janssen Pharmaceuticals. The other authors have no disclosures to report.
